Hospitalized COVID-19 patients with cognitive complaints demonstrate reduced attention and executive dysfunction on formal cognitive testing consistent with the same frequency and pattern of cognitive changes associated with critical illness.
Individuals with Parkinson’s disease dementia and orthostatic hypotension (OH) have more robust cognitive improvement from rivastigmine compared to those without OH. This greater response possibly is mediated by the anti-OH effect of rivastigmine.
In a randomized, double-blind, placebo-controlled trial of Fortasyn Connect (Souvenaid), a nutraceutical drink, patients with prodromal Alzheimer’s disease demonstrated, over a 36-month period, a slower decline in cognitive functions compared to the control group.
SYNOPSIS: In this large prospective cohort study of subjects in Manhattan, researchers demonstrated an association between exposure to air pollution and decline in cognitive function over time in one cohort, but not the other.
Covert brain infarcts are detected on magnetic resonance imaging studies in the aging brain in about 10% of people at age 65 years, increasing to 25% at age 80 years. Most patients who develop dementia have a combination of multiple small infarcts, plus amyloid deposition. Prevention of covert infarcts is a strategy to mitigate the frequency and severity of late-life dementia.
One major health problem related to COVID-19 involves neurological symptoms and signs of brain injury. Patients with COVID-19 can experience acute periods of confusion, post-traumatic amnesia, and delirium. Physicians and researchers do not know what will happen to patients with COVID-19 over the long term and whether they will fully regain their prior cognitive status.
This randomized, controlled trial notes improvement in measures of executive functioning, such as organization and planning, in elderly Chinese participants with mild cognitive impairment who were selected to play mahjong three times weekly for 12 weeks.
Cilostazol is a phosphodiesterase 3 inhibitor widely used in Asia for secondary stroke prevention but approved for use in North America only for symptomatic peripheral vascular disease. It has been theorized that cilostazol might be beneficial in preventing the progression of small vessel disease in the brain and, therefore, may have a secondary effect in preventing vascular dementia.
Healthcare workers and patients who have contracted SARS-CoV-2, particularly if they were hospitalized, could be at risk of neurological deficits in the short term and as well as later cognitive problems.